#United States #Boston #biotechnology #Arbele Limited #BCIC

Arbele Limited Secures Top Honor at BCIC's 4th Annual Biomedical Pitch Competition

Arbele Limited, an emerging biotech firm based in Hong Kong, has achieved a remarkable milestone by winning first place at the 4th Annual Biomedical Pitch Competition hosted by the Boston Capital Investment Club (BCIC). Competing against over 170 companies from the United States and Asia, Arbele's innovative research into CDH17-targeted immunotherapy was recognized as groundbreaking in the fight against gastrointestinal cancers.

The company specializes in developing revolutionary treatments that target cadherin-17 (CDH17), a biomarker significantly present in various digestive tract malignancies. Their leading candidate, Cabotamig (ARB202), is a pioneering T-cell engager specifically designed to bind CDH17 and CD3. This targeting approach allows it to potentially treat a wide range of gastrointestinal cancers. In early Phase I clinical studies, Cabotamig demonstrated promising safety and survival results among patients with heavily pretreated and drug-resistant tumors, showcasing efficacy comparable to existing T-cell engagers used in solid tumors.

Alongside Cabotamig, Arbele is progressing with several Antibody-Drug Conjugate (ADC) initiatives, including biparatopic and bispecific targets, as well as innovative dual payloads. The company has outlined plans for regulatory submissions in the U.S. and China, indicating a proactive approach to market introduction. The judges of the competition praised Arbele for its well-balanced platform that prioritizes tumor specificity while minimizing off-target toxicity.

Keynote Insights and Competition Highlights

The BCIC event featured notable figures in the biomedical field, including Mr. Albert Wong, Chief Executive Officer of the Hong Kong Science and Technology Parks Corporation (HKSTP). Wong underscored the growing biomedical ecosystem in Hong Kong, emphasizing the importance of cross-border collaborations in sparking innovation. Dr. Qiusong Tang, the head of the Roche Accelerator, shared valuable insights about external innovation strategies and stressed the significance of sustaining scalable, clinically viable startups within the competitive landscape.

This year's competition, which saw submissions from over 170 applicants, culminated in the selection of 17 standout finalists. Arbele's victory not only amplifies the recognition of its innovative CDH17-targeting platform but also enhances its fundraising, regulatory, and commercialization momentum. Since its inception in 2022, the BCIC competition has catalyzed investment deals exceeding $100 million, highlighting its critical role in advancing biotech initiatives globally.

A Forward-Looking Vision for Arbele

Established in 2022, Arbele Limited is a clinical-stage biotechnology firm focused on developing pioneering immunotherapeutic solutions to combat digestive tract cancers. With a strategic emphasis on CDH17-targeted T-cell engagers and ADCs, the company's mission aims to significantly improve patient survival outcomes where conventional treatment options are lacking. For more detailed information, visit Arbele's official website.

About the Boston Capital Investment Club

The Boston Capital Investment Club (BCIC) connects nascent companies with a network of over 300 institutional and angel investors worldwide. Renowned for its expertise in business incubation and strategic alliances, BCIC has emerged as a leading cross-border investment platform in North America. To learn more about BCIC's initiatives, visit BCIC Global.